Application of combined markers in predicting survival and efficacy of immune checkpoint inhibitors in tumor patients
By using the ISG15+ macrophage to SPP1+ macrophage infiltration ratio (ISRatio) as an indicator, we have addressed the problem of poor treatment efficacy caused by the complex regulatory network of the tumor immunosuppressive microenvironment, and achieved accurate prediction of the survival time of cancer patients and the efficacy of immune checkpoint inhibitor therapy, as well as personalized treatment guidance.
CN120847401BActive Publication Date: 2026-07-21XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF 2 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
- Filing Date
- 2025-07-24
- Publication Date
- 2026-07-21
Smart Images
Figure CN120847401B_ABST
Abstract
The application discloses application of a combination marker in survival time of tumor patients and treatment effect prediction of an immune checkpoint inhibitor, and proposes an ISG15 + macrophages and SPP1 + The macrophage infiltration level is used as the combination marker, the ratio of the two is used as a kit for the survival time of tumor patients and the treatment effect of the immune checkpoint inhibitor, the survival time of tumor objects and the treatment effect of the tumor immune checkpoint inhibitor can be effectively predicted, patients sensitive to the immune checkpoint inhibitor treatment can be effectively screened, the response rate of the tumor immune checkpoint inhibitor treatment is improved, and the combination marker has good clinical transformation and application prospect.
Need to check novelty before this filing date? Find Prior Art